LIC Healthcare Fund - Regular Plan - Growth
LIC Mutual Fund
₹32.31 (+0.78%)
NAV as of 9 Oct 2026
Minimum Investment: ₹5,000
Return
9.04% Returns for 1Y
Expense ratio & Others
- Net expense ratio
- 2.29%
- Exit load
- 0%
- Lock-in
- No
- Minimum investment
- ₹5,000
- Category
- Sector - Healthcare
Expense ratio is inclusive of GST. Returns may be taxed based on the fund type and your holding period — please read the scheme-related documents and consult a tax advisor. Figures are historical and do not guarantee future results.
Fund Returns Estimator
One-time investment
₹1,000
6 months
₹1,166
Invested ₹1,000
▲+16.57%1 year
₹1,090
Invested ₹1,000
▲+9.04%3 years
₹1,194
Invested ₹1,000
▲+19.36%5 years
₹1,104
Invested ₹1,000
▲+10.37%
Based on the fund’s historic trailing returns — a planning illustration, not a guarantee of future results.
Invest One-TimePlan it your way
The figures above are fixed to this fund’s past returns over set periods. Use a calculator to set your own amount, tenure and expected rate of return.
Risk level
Riskometer scale
- Low
- Low to Moderate
- Moderate
- Moderate to High
- High
- Very HighThis fund
Riskometer level assigned by the fund house as per SEBI norms. It can change as the scheme’s portfolio changes.
Fund benchmark
| Primary Index Name | BSE Healthcare PR INR |
|---|---|
| Secondary Index Name | BSE Healthcare PR INR |
| Index Name | BSE Healthcare TR INR |
| Weighting | 100% |
Returns
| 1Y | 3Y | 5Y | 10Y | |
|---|---|---|---|---|
| Fund returns (%) | +9.04% | +19.36% | +10.37% | — |
| Cumulative returns (%) | +9.04% | +70.05% | +63.78% | — |
Fund Manager
| Manager | Dhaval Sangoi |
|---|---|
| Role | Manager |
| Manager Tenure | 0.08 yrs |
About Fund
| Date of Incorporation | 28 Feb 2019 |
|---|---|
| Fund House | LIC Mutual Fund |
| Custodian | Standard Chartered Bank - India |
| Registrar / Transfer Agent | LIC Mutual Fund Asset Management Limited |
| Address | Standard Chartered Bank - India |
Top Holdings
| Company | Weightage (%) |
|---|---|
| Sun Pharmaceuticals Industries Ltd | 10.09% |
| Divi's Laboratories Ltd | 9.29% |
| Torrent Pharmaceuticals Ltd | 6.45% |
| Neuland Laboratories Ltd | 6.38% |
| Apollo Hospitals Enterprise Ltd | 6.23% |
| Cipla Ltd | 5.68% |
| Navin Fluorine International Ltd | 5.65% |
| Aurobindo Pharma Ltd | 5.17% |
| Aster DM Quality Care Ltd Ordinary Shares | 4.82% |
| Zydus Lifesciences Ltd | 4.79% |
| OneSource Specialty Pharma Ltd | 4.56% |
| Piramal Pharma Ltd | 4.33% |
| Fortis Healthcare Ltd | 4.16% |
| Gland Pharma Ltd | 3.93% |
| Alkem Laboratories Ltd | 3.44% |
| Glenmark Pharmaceuticals Ltd | 3.41% |
| Ipca Laboratories Ltd | 3.40% |
| Abbott India Ltd | 3.39% |
Investment Strategy
The objective of the Scheme is to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. However there can be no assurance that the investment objective under the scheme will be realized.
Long term capital appreciation
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. The data shown is for information only and does not constitute investment advice.